Abstract
Multiple endocrine neoplasia type 2 (MEN2) is a rare hereditary syndrome due to mutations of the proto-oncogene REarranged during Transfection (RET), defined by the association of medullary thyroid carcinoma (MTC) in almost 100% cases, and pheochromocytoma in roughly 50% (primary hyperparathyroidism can be seen in 10–20% of patients with MEN2A). Early thyroidectomy and the efficacy of novel tyrosine kinase inhibitors modified the natural history of MTC, with possibilities of cure or long-term control. The second main compound, pheochromocytoma, is reported with a variable penetrance, from 10 to 80% cases, depending on the mutation of RET. Pheochromocytoma constitutes the main disease to screen in patients with RET mutations. Pheochromocytoma clinical and biochemical diagnosis, as well as the way to treat it are thus crucial. This review will thus focus on the epidemiological specificities of MEN2-related pheochromocytoma, the genotype/phenotype relationship, the modern imaging modalities necessary to confirm the diagnosis in this hereditary context, as well as the optimal management and the possibilities of adrenal sparing surgery. Additional information will include the natural history of MEN2B-pheochromocytoma, the rare cases of malignant pheochromocytoma, and the factors that could modify the penetrance between individuals carrying the same mutation, especially in the same family.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Change history
02 June 2020
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
References
C. Eng, D.P. Smith, L.M. Mulligan, M.A. Nagai, C.S. Healey, M.A. Ponder, E. Gardner, G.F. Scheumann, C.E. Jackson, A. Tunnacliffe, Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum. Mol. Genet. 3, 237–241 (1994)
J.S. Mathiesen, J.P. Kroustrup, P. Vestergaard, K. Stochholm, P.L. Poulsen, Å.K. Rasmussen, U. Feldt-Rasmussen, S. Schytte, S.C. Londero, H.B. Pedersen, C.H. Hahn, J. Bentzen, S. Möller, M. Gaustadnes, M. Rossing, F.C. Nielsen, K. Brixen, A.L. Frederiksen, C. Godballe, Danish Thyroid Cancer Group (DATHYRCA), Completeness of RET testing in patients with medullary thyroid carcinoma in Denmark 1997-2013: a nationwide study. Clin. Epidemiol. 11, 93–99 (2019). https://doi.org/10.2147/CLEP.S183268
S.A. Wells Jr, S.L. Asa, H. Dralle, R. Elisei, D.B. Evans, R.F. Gagel, N. Lee, A. Machens, J.F. Moley, F. Pacini, F. Raue, K. Frank-Raue, B. Robinson, M.S. Rosenthal, M. Santoro, M. Schlumberger, M. Shah, S.G. Waguespack, C. American Thyroid Association Guidelines Task Force on Medullary Thyroid, Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25, 567–610 (2015). https://doi.org/10.1089/thy.2014.0335
F. Castinetti, J. Moley, L. Mulligan, S.G. Waguespack, A comprehensive review on MEN2B. Endocr. Relat. Cancer 25, T29–T39 (2018). https://doi.org/10.1530/ERC-17-0209
J.S. Mathiesen, J.P. Kroustrup, P. Vestergaard, K. Stochholm, P.L. Poulsen, A.K. Rasmussen, U. Feldt-Rasmussen, M. Gaustadnes, T.F. Orntoft, T. van Overeem Hansen, F.C. Nielsen, K. Brixen, C. Godballe, A.L. Frederiksen, Distribution of RET mutations in multiple endocrine neoplasia 2 in Denmark 1994–2014: a nationwide study. Thyroid 27, 215–223 (2017). https://doi.org/10.1089/thy.2016.0411
J. S. Mathiesen, J. P. Kroustrup, P. Vestergaard, M. Madsen, K. Stochholm, P. L. Poulsen, A. Krogh Rasmussen, U. Feldt-Rasmussen, S. Schytte, H. B. Pedersen, C. H. Hahn, J. Bentzen, M. Gaustadnes, T. F. Orntoft, T. V. O. Hansen, F. C. Nielsen, K. Brixen, A. L. Frederiksen, C. Godballe, Incidence and prevalence of multiple endocrine neoplasia 2B in Denmark: a nationwide study. Endocr. Relat. Cancer (2017). https://doi.org/10.1530/ERC-17-0122
S.A. Wells Jr, F. Pacini, B.G. Robinson, M. Santoro, Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J. Clin. Endocrinol. Metab. 98, 3149–3164 (2013). https://doi.org/10.1210/jc.2013-1204
A. Machens, M. Elwerr, K. Lorenz, F. Weber, H. Dralle, Long-term outcome of prophylactic thyroidectomy in children carrying RET germline mutations. Br. J. Surg. 105, e150–e157 (2018). https://doi.org/10.1002/bjs.10746
S. Thosani, M. Ayala-Ramirez, L. Palmer, M.I. Hu, T. Rich, R.F. Gagel, G. Cote, S.G. Waguespack, M.A. Habra, C. Jimenez, The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. J. Clin. Endocrinol. Metab. 98, E1813–E1819 (2013). https://doi.org/10.1210/jc.2013-1653
F. Castinetti, X.P. Qi, M.K. Walz, A.L. Maia, G. Sanso, M. Peczkowska, K. Hasse-Lazar, T.P. Links, S. Dvorakova, R.A. Toledo, C. Mian, M.J. Bugalho, N. Wohllk, O. Kollyukh, L. Canu, P. Loli, S.R. Bergmann, J. Biarnes Costa, O. Makay, A. Patocs, M. Pfeifer, N.S. Shah, T. Cuny, M. Brauckhoff, B. Bausch, E. von Dobschuetz, C. Letizia, M. Barczynski, M.K. Alevizaki, M. Czetwertynska, M.U. Ugurlu, G. Valk, J.T. Plukker, P. Sartorato, D.R. Siqueira, M. Barontini, M. Szperl, B. Jarzab, H.H. Verbeek, T. Zelinka, P. Vlcek, S.P. Toledo, F.L. Coutinho, M. Mannelli, M. Recasens, L. Demarquet, L. Petramala, S. Yaremchuk, D. Zabolotnyi, F. Schiavi, G. Opocher, K. Racz, A. Januszewicz, G. Weryha, J.F. Henry, T. Brue, B. Conte-Devolx, C. Eng, H.P. Neumann, Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncol. 15, 648–655 (2014). https://doi.org/10.1016/S1470-2045(14)70154-8
L. Nguyen, P. Niccoli-Sire, P. Caron, D. Bastie, B. Maes, G. Chabrier, O. Chabre, V. Rohmer, P. Lecomte, J.F. Henry, B. Conte-Devolx, G. French Calcitonin, Tumors study, Pheochromocytoma in multiple endocrine neoplasia type 2: a prospective study. Eur. J. Endocrinol. 144, 37–44 (2001)
T. Imai, S. Uchino, T. Okamoto, S. Suzuki, S. Kosugi, T. Kikumori, A. Sakurai, Men Consortium of Japan, High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. Eur. J. Endocrinol. 168, 683–687 (2013). https://doi.org/10.1530/EJE-12-1106
R. K. Voss, L. Feng, J. E. Lee, N. D. Perrier, P. H. Graham, S. M. Hyde, F. Nieves-Munoz, M. E. Cabanillas, S. G. Waguespack, G. J. Cote, R. F. Gagel, E. G. Grubbs, Medullary thyroid carcinoma in MEN2A: ATA moderate or high-risk RET mutations do not predict disease aggressiveness, J. Clin. Endocrinol. Metab. (2017). https://doi.org/10.1210/jc.2017-00317
F. Castinetti, S.G. Waguespack, A. Machens, S. Uchino, K. Hasse-Lazar, G. Sanso, T. Else, S. Dvorakova, X.P. Qi, R. Elisei, A.L. Maia, J. Glod, D.M. Lourenço, N. Valdes, J. Mathiesen, N. Wohllk, T.R. Bandgar, D. Drui, M. Korbonits, M.R. Druce, C. Brain, T. Kurzawinski, A. Patocs, M.J. Bugalho, A. Lacroix, P. Caron, P. Fainstein-Day, F. Borson Chazot, M. Klein, T.P. Links, C. Letizia, L. Fugazzola, O. Chabre, L. Canu, R. Cohen, A. Tabarin, A. Spehar Uroic, D. Maiter, S. Laboureau, C. Mian, M. Peczkowska, F. Sebag, T. Brue, D. Mirebeau-Prunier, L. Leclerc, B. Bausch, A. Berdelou, A. Sukurai, P. Vlcek, J. Krajewska, M. Barontini, C. Vaz Ferreira Vargas, L. Valerio, L. Ceolin, S. Akshintala, A. Hoff, C. Godballe, B. Jarzab, C. Jimenez, C. Eng, T. Imai, M. Schlumberger, E. Grubbs, H. Dralle, H.P. Neumann, E. Baudin, Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes Endocrinol. 7, 213–220 (2019). https://doi.org/10.1016/S2213-8587(18)30336-X
F. Raue, H. Dralle, A. Machens, T. Bruckner, K. Frank-Raue, Long-term survivorship in multiple endocrine neoplasia type 2B diagnosed before and in the new millennium. J. Clin. Endocrinol. Metab. 103, 235–243 (2018). https://doi.org/10.1210/jc.2017-01884
M.D. Castellone, A. Verrienti, D. Magendra Rao, M. Sponziello, D. Fabbro, M. Muthu, C. Durante, M. Maranghi, G. Damante, S. Pizzolitto, G. Costante, D. Russo, M. Santoro, S. Filetti, A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization. Clin. Endocrinol. 73, 529–534 (2010). https://doi.org/10.1111/j.1365-2265.2009.03757.x
F. Castinetti, A.L. Maia, M. Peczkowska, M. Barontini, K. Hasse-Lazar, T.P. Links, R.A. Toledo, S. Dvorakova, C. Mian, M.J. Bugalho, S. Zovato, M. Alevizaki, A. Kvachenyuk, B. Bausch, P. Loli, S.R. Bergmann, A. Patocs, M. Pfeifer, J.B. Costa, E. von Dobschuetz, C. Letizia, G. Valk, M. Barczynski, M. Czetwertynska, J.T.M. Plukker, P. Sartorato, T. Zelinka, P. Vlcek, S. Yaremchuk, G. Weryha, L. Canu, N. Wohllk, F. Sebag, M.K. Walz, C. Eng, H.P.H. Neumann, The penetrance of MEN2 pheochromocytoma is not only determined by RET mutations. Endocr. Relat. Cancer 24, L63–L67 (2017). https://doi.org/10.1530/ERC-17-0189
D.R. Siqueira, L. Ceolin, C.V. Ferreira, M. Romitti, S.C. Maia, L.M. Maciel, A.L. Maia, Role of RET genetic variants in MEN2-associated pheochromocytoma. Eur. J. Endocrinol. 170, 821–828 (2014). https://doi.org/10.1530/EJE-14-0084
M. Lebeault, S. Pinson, M. Guillaud-Bataille, A.-P. Gimenez-Roqueplo, A. Carrie, V. Barbu, P. Pigny, S. Bezieau, J.-M. Rey, C. Delvincourt, S. Giraud, C. Veyrat-Durebex, P. Saulnier, N. Bouzamondo, M. Chabbert, J. Blin, A. Mohamed, P. Romanet, F. Borson-Chazot, V. Rohmer, A. Barlier, D. Mirebeau-Prunier, Nationwide French study of RET variants detected from 2003 to 2013 suggests a possible influence of polymorphisms as modifiers. Thyroid 27, 1511–1522 (2017). https://doi.org/10.1089/thy.2016.0399
M. Kaczmarek-Ryś, K. Ziemnicka, A. Pławski, B. Budny, M. Michalak, S. Hryhorowicz, J. Hoppe-Gołębiewska, P. Boruń, M. Gołąb, M. Czetwertyńska, M. Sromek, M. Szalata, M. Ruchała, R. Słomski, Modifying impact of RET gene haplotypes on medullary thyroid carcinoma clinical course. Endocr. Relat. Cancer 25, 421–436 (2018). https://doi.org/10.1530/ERC-17-0452
M. Oczko-Wojciechowska, M. Swierniak, J. Krajewska, M. Kowalska, M. Kowal, T. Stokowy, B. Wojtas, D. Rusinek, A. Pawlaczek, A. Czarniecka, S. Szpak-Ulczok, T. Gawlik, E. Chmielik, T. Tyszkiewicz, B. Nikiel, D. Lange, M. Jarzab, M. Wiench, B. Jarzab, Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations. Sci. Rep. 7, 42074 (2017). https://doi.org/10.1038/srep42074
K. Pacak, S. H. Tella, Pheochromocytoma and Paraganglioma, in: K. R. Feingold, B. Anawalt, A. Boyce, G. Chrousos, K. Dungan, A. Grossman, J. M. Hershman, G. Kaltsas, C. Koch, P. Kopp, M. Korbonits, R. McLachlan, J. E. Morley, M. New, L. Perreault, J. Purnell, R. Rebar, F. Singer, D. L. Trence, A. Vinik, D. P. Wilson (Eds.), Endotext, MDText.com, Inc., South Dartmouth (MA), 2000. http://www.ncbi.nlm.nih.gov/books/NBK481899/. Accessed 11 Feb 2019
J.W. Lenders, G. Eisenhofer, M. Mannelli, K. Pacak, Phaeochromocytoma. Lancet 366, 665–675 (2005). https://doi.org/10.1016/S0140-6736(05)67139-5
G. Eisenhofer, A. Prejbisz, M. Peitzsch, C. Pamporaki, J. Masjkur, N. Rogowski-Lehmann, K. Langton, E. Tsourdi, M. Pęczkowska, S. Fliedner, T. Deutschbein, F. Megerle, H. J. L. M. Timmers, R. Sinnott, F. Beuschlein, M. Fassnacht, A. Januszewicz, J. W. M. Lenders, Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated o-methylated catecholamine metabolites, Clin. Chem. (2018). https://doi.org/10.1373/clinchem.2018.291369
R. Därr, M. Kuhn, C. Bode, S.R. Bornstein, K. Pacak, J.W.M. Lenders, G. Eisenhofer, Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review. Endocrine 56, 495–503 (2017). https://doi.org/10.1007/s12020-017-1300-y
L. Canu, J.A.W. Van Hemert, M.N. Kerstens, R.P. Hartman, A. Khanna, I. Kraljevic, D. Kastelan, C. Badiu, U. Ambroziak, A. Tabarin, M. Haissaguerre, E. Buitenwerf, A. Visser, M. Mannelli, W. Arlt, V. Chortis, I. Bourdeau, N. Gagnon, M. Buchy, F. Borson-Chazot, T. Deutschbein, M. Fassnacht, A. Hubalewska-Dydejczyk, M. Motyka, E. Rzepka, R.T. Casey, B.G. Challis, M. Quinkler, L. Vroonen, A. Spyroglou, F. Beuschlein, C. Lamas, W.F. Young, I. Bancos, H.J.L.M. Timmers, CT characteristics of pheochromocytoma: relevance for the evaluation of adrenal incidentaloma. J. Clin. Endocrinol. Metab. 104, 312–318 (2019). https://doi.org/10.1210/jc.2018-01532
E. Korpershoek, B.-J. Petri, E. Post, C.H.J. van Eijck, R.A. Oldenburg, E.J.T. Belt, W.Wde Herder, R.R. de Krijger, W.N.M. Dinjens, Adrenal medullary hyperplasia is a precursor lesion for pheochromocytoma in MEN2 syndrome. Neoplasia 16, 868–873 (2014). https://doi.org/10.1016/j.neo.2014.09.002
F. Castinetti, A. Kroiss, R. Kumar, K. Pacak, D. Taieb, 15 years of paraganglioma: imaging and imaging-based treatment of pheochromocytoma and paraganglioma. Endocr. Relat. Cancer 22, T135–T145 (2015). https://doi.org/10.1530/ERC-15-0175
B. Havekes, K. King, E.W. Lai, J.A. Romijn, E.P.M. Corssmit, K. Pacak, New imaging approaches to phaeochromocytomas and paragangliomas. Clin. Endocrinol. 72, 137–145 (2010). https://doi.org/10.1111/j.1365-2265.2009.03648.x
S.A. Shamim, A. Kumar, R. Kumar, PET/computed tomography in neuroendocrine tumor: value to patient management and survival outcomes. PET Clin. 10, 411–421 (2015). https://doi.org/10.1016/j.cpet.2015.03.005
D. Taïeb, H.J. Timmers, E. Hindié, B.A. Guillet, H.P. Neumann, M.K. Walz, G. Opocher, W.Wde. Herder, C.C. Boedeker, R.R. de Krijger, A. Chiti, A. Al-Nahhas, K. Pacak, D. Rubello, EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur. J. Nucl. Med. Mol. Imaging 39, 1977–1995 (2012). https://doi.org/10.1007/s00259-012-2215-8
H.J.L.M. Timmers, C.C. Chen, J.A. Carrasquillo, M. Whatley, A. Ling, B. Havekes, G. Eisenhofer, L. Martiniova, K.T. Adams, K. Pacak, Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J. Clin. Endocrinol. Metab. 94, 4757–4767 (2009). https://doi.org/10.1210/jc.2009-1248
D. Taïeb, R.J. Hicks, E. Hindié, B.A. Guillet, A. Avram, P. Ghedini, H.J. Timmers, A.T. Scott, S. Elojeimy, D. Rubello, I.J. Virgolini, S. Fanti, S. Balogova, N. Pandit-Taskar, K. Pacak, European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur. J. Nucl. Med. Mol. Imaging 46, 2112–2137 (2019). https://doi.org/10.1007/s00259-019-04398-1
A. Imperiale, K. Elbayed, F.-M. Moussallieh, N. Reix, M. Piotto, J.-P. Bellocq, B. Goichot, P. Bachellier, I.-J. Namer, Metabolomic profile of the adrenal gland: from physiology to pathological conditions. Endocr. Relat. Cancer 20, 705–716 (2013). https://doi.org/10.1530/ERC-13-0232
C. Veyrat-Durebex, N. Bouzamondo, M. Le Mao, J.M. Chao de la Barca, C. Bris, X. Dieu, G. Simard, C. Gadras, L. Tessier, D. Drui, F. Borson-Chazot, A. Barlier, P. Reynier, D. Prunier-Mirebeau, Metabolomics signatures of a subset of RET variants according to their oncogenic risk level. Endocr. Relat. Cancer 26, 379–389 (2019). https://doi.org/10.1530/ERC-18-0314
A. Scholten, M.R. Vriens, G.J.E. Cromheecke, I.H.M. Borel Rinkes, G.D. Valk, Hemodynamic instability during resection of pheochromocytoma in MEN versus non-MEN patients. Eur. J. Endocrinol. 165, 91–96 (2011). https://doi.org/10.1530/EJE-11-0148
J.W.M. Lenders, Q.-Y. Duh, G. Eisenhofer, A.-P. Gimenez-Roqueplo, S.K.G. Grebe, M.H. Murad, M. Naruse, K. Pacak, W.F. Young, Endocrine Society, Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 1915–1942 (2014). https://doi.org/10.1210/jc.2014-1498
E.G. Grubbs, T.A. Rich, C. Ng, P.R. Bhosale, C. Jimenez, D.B. Evans, J.E. Lee, N.D. Perrier, Long-term outcomes of surgical treatment for hereditary pheochromocytoma. J. Am. Coll. Surg. 216, 280–289 (2013). https://doi.org/10.1016/j.jamcollsurg.2012.10.012
F. Castinetti, D. Taieb, J.F. Henry, M. Walz, C. Guerin, T. Brue, B. Conte-Devolx, H.P.H. Neumann, F. Sebag, Management of endocrine disease: outcome of adrenal sparing surgery in heritable pheochromocytoma. Eur. J. Endocrinol. 174, R9–R18 (2016). https://doi.org/10.1530/EJE-15-0549
K.J. Rowland, R.D. Chernock, J.F. Moley, Pheochromocytoma in an 8-year-old patient with multiple endocrine neoplasia type 2A: implications for screening. J. Surg. Oncol. 108, 203–206 (2013). https://doi.org/10.1002/jso.23378
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Amodru, V., Taieb, D., Guerin, C. et al. MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives. Endocrine 69, 496–503 (2020). https://doi.org/10.1007/s12020-020-02332-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-020-02332-2